ITGB1 and neoplasm: The in vivo validation using subcutaneous xenografts demonstrated that sorafenib significantly reduced tumor volume and weight under ITGB1 silencing compared to controls (Fig. 5H–J), with parallel suppression of Ki67+ proliferative cells (Fig. 5K, L).